Progress toward resistance mechanism to epidermal growth factor receptor tyrosine kinase inhibitor
The EGFR signaling pathway plays an important role in the occurrence and development of many malignant tumors. It has become a hot spot in the treatment of advanced cancer. At present, the small molecule epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has been shown to advance...
Main Authors: | Zhang Lingling, Zhang Xiaoxue, Zhao Liang |
---|---|
Format: | Article |
Language: | English |
Published: |
De Gruyter
2016-01-01
|
Series: | Open Life Sciences |
Subjects: | |
Online Access: | https://doi.org/10.1515/biol-2016-0056 |
Similar Items
-
Continuous EGFR tyrosine kinase inhibitor treatment with or without chemotherapy beyond gradual progression in non-small cell lung cancer patients
by: Peng L, et al.
Published: (2017-08-01) -
Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and Future
by: Walid Shalata, et al.
Published: (2021-08-01) -
Should Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Be Continued beyond Progressive Disease
by: Young Hak Kim, et al.
Published: (2011-09-01) -
Evaluation of Patients with Lung Cancer Treated with Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
by: Laksmi Wulandari, et al.
Published: (2018-07-01) -
Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
by: Xu H, et al.
Published: (2019-07-01)